Keytruda

Merck’s CEO Kenneth Frazier to retire after ten years in the role

Under his leadership, Merck has seen impressive growth for its immunotherapy blockbuster Keytruda (pembrolizumab) and other innovative treatments.

BMS gains FDA approval for second Opdivo combo in kidney cancer

Armed with two Opdivo combinations in its arsenal, BMS is primed to take on Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) plus Pfizer’s TKI Inlyta (ipilimumab). ... Keytruda/Inlyta won an FDA approval in advanced RCC in

BMS aims for US approval of Opdivo combo in stomach cancer

If Opdivo wins an approval for first-line gastric cancer, it could gain an advantage over Merck &Co’s (MSD) rival checkpoint inhibitor Keytruda (pembrolizumab). ... In the Keynote-062 trial, Keytruda plus chemotherapy was not found to be statistically

New dosing option for AZ’s Imfinzi approved in the EU and UK

Merck &Co’s checkpoint inhibitor Keytruda (pembrolizumab) currently holds much of the NSCLC market, although the drug failed to show benefit in ES-SCLC when added to chemotherapy.

GSK pays $85m upfront for Surface Oncology’s lead cancer drug

The company is also collaborating with Merck &Co (MSD) on a clinical trial evaluating the safety and efficacy of SRF617 in combination with Merck’s blockbuster PD-1 inhibitor Keytruda (pembrolizumab).

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]